Fig. 5
A side-by-side assessment of significantly over-represented transcription factor binding site pathways associated with the immunisation of mice with one of two heterologous viral vector vaccine prime-boost combinations, 24 h after the boost dose. a Overlap between significantly differentially expressed genes in mouse whole blood 24 h after immunisation with one of a series of candidate viral vector vaccines, administered as a single dose or heterologous prime-boost combination. Significantly differentially expressed genes (DEGs) were defined as those with an FDR < 0.01. The intersection between the two ovals indicates common DEGs between the two conditions. The number of significantly DEGs in each group is denoted by “n”. b Gene expression changes induced in mice 24 h after the boost dose of either a human adenovirus serotype 5 vaccine encoding a factor H binding protein (fHbp) transgene (Ad-fHbp) prime, modified vaccinia Ankara (MVA)-fHbp boost, or an MVA-fHbp prime, Ad-fHbp boost heterologous vaccine combination were contrasted to determine significantly DEGs associated with each vaccine combination. Pathway over-representation analysis was performed on these DEGs to determine the enrichment of transcription factor binding site pathway categories from the publicly available CisRED database. c MVA-fHbp prime, Ad-fHbp boost. d Ad-fHbp prime, MVA-fHbp boost. The x-axes correspond to the negative log10 pathway p-value associated with each pathway (y-axes). The dashed red lines correspond to a negative log10 pathway p-value of 0.05